References and Notes
For reviews, see:
<A NAME="RS03610ST-1A">1a</A>
DeKorver KA.
Li H.
Lohse AG.
Hayashi R.
Lu Z.
Zhang Y.
Hsung RP.
Chem.
Rev.
2010,
110: in press
<A NAME="RS03610ST-1B">1b</A>
Evano G.
Coste A.
Jouvin K.
Angew.
Chem. Int. Ed.
2010,
49:
2840
For examples in 2010, see:
<A NAME="RS03610ST-2A">2a</A>
Li H.
Antoline JE.
Yang J.-H.
Al-Rashid ZF.
Hsung RP.
New J. Chem.
2010,
34: in
press
<A NAME="RS03610ST-2B">2b</A>
Kramer S.
Madsen JLH.
Rottländer M.
Skrydstrup T.
Org.
Lett.
2010,
12:
2758
<A NAME="RS03610ST-2C">2c</A>
Banerjee B.
Litvinov DN.
Kang J.
Bettale JD.
Castle SL.
Org. Lett.
2010,
12:
2650
<A NAME="RS03610ST-2D">2d</A>
Gourdet B.
Rudkin ME.
Lam HW.
Org.
Lett.
2010,
12:
2554
<A NAME="RS03610ST-2E">2e</A>
Jia W.
Jiao N.
Org. Lett.
2010,
12:
2000
<A NAME="RS03610ST-2F">2f</A>
Burley GA.
Davies DL.
Griffith GA.
Lee M.
Singh K.
J. Org. Chem.
2010,
75:
980
<A NAME="RS03610ST-2G">2g</A>
Yamasaki R.
Terashima N.
Sotome I.
Komagawa S.
Saito S.
J.
Org. Chem.
2010,
75:
480
<A NAME="RS03610ST-3">3</A>
Zhang Y.
DeKorver KA.
Lohse AG.
Zhang Y.-S.
Huang J.
Hsung RP.
Org.
Lett.
2009,
11:
899
<A NAME="RS03610ST-4">4</A>
DeKorver KA.
Hsung RP.
Lohse AG.
Zhang Y.
Org. Lett.
2010,
12:
1840
For leading reviews on aza-Claisen
rearrangements, see:
<A NAME="RS03610ST-5A">5a</A>
Majumdar KC.
Bhayyacharyya T.
Chattopadhyay B.
Nandi RK.
Synthesis
2009,
2117
<A NAME="RS03610ST-5B">5b</A>
Nubbemeyer U.
Top
Curr. Chem.
2005,
244:
149
For some examples of aza-Claisen rearrangements, see:
<A NAME="RS03610ST-5C">5c</A>
Majumdar KC.
Samanta S.
Chattopadhyay B.
Nandi RK.
Synthesis
2010,
863
<A NAME="RS03610ST-5D">5d</A>
Cheung LLW.
Yudin AK.
Org.
Lett.
2009,
11:
1281
<A NAME="RS03610ST-5E">5e</A>
Cant AA.
Bertrand GHV.
Henderson JL.
Roberts L.
Greaney MF.
Angew. Chem. Int.
Ed.
2009,
48:
5199
For reviews on the chemistry of
ketenimines, see:
<A NAME="RS03610ST-6A">6a</A>
Krow GR.
Angew. Chem., Int. Ed. Engl.
1971,
10:
435
<A NAME="RS03610ST-6B">6b</A>
Gambaryan NP.
Usp. Khim.
1976,
45:
1251
<A NAME="RS03610ST-6C">6c</A>
Dondoni A.
Heterocycles
1980,
14:
1547
<A NAME="RS03610ST-6D">6d</A>
Barker MW.
McHenry WE. In The Chemistry of Ketenes, Allenes and Related
Compounds
Part 2:
Patai S.
Wiley-Interscience;
Chichester:
1980.
p.701-720
<A NAME="RS03610ST-6E">6e</A>
Alajarin M.
Vidal A.
Tovar F.
Targets
Heterocycl. Syst.
2000,
4:
293
For examples of imidates serving
as prodrugs, see:
<A NAME="RS03610ST-7A">7a</A>
Maryanoff BE.
McComsey DF.
Costanzo MJ.
Yabut SC.
Lu T.
Player MR.
Giardino EC.
Damiano BP.
Chem. Biol. Drug. Des.
2006,
68:
29
<A NAME="RS03610ST-7B">7b</A>
Poon SF.
Stock N.
Payne JE.
McGuire AR.
Stearns B.
Yang X.
Chen W.
Munoz B.
Smith ND.
Bioorg.
Med. Chem. Lett.
2005,
15:
2259
<A NAME="RS03610ST-7C">7c</A>
Bundgaard H.
Drustrup Larsen J.
J. Med. Chem.
1988,
31:
2066
For recent examples of amidine formation,
see:
<A NAME="RS03610ST-8A">8a</A>
Shang Y.
He X.
Hu J.
Wu J.
Zhang M.
Yu S.
Zhang Q.
Adv. Synth. Catal.
2009,
351:
2709
<A NAME="RS03610ST-8B">8b</A>
She J.
Jiang Z.
Wang Y.
Synlett
2009,
2023
<A NAME="RS03610ST-8C">8c</A>
Yu RT.
Rovis T.
J. Am. Chem. Soc.
2008,
130:
3262
<A NAME="RS03610ST-8D">8d</A>
Yoo EJ.
Ahlquist M.
Bae I.
Sharpless B.
Fokin V.
Chang S.
J.
Org. Chem.
2008,
73:
5520
For recent examples of imidate formation,
see:
<A NAME="RS03610ST-9A">9a</A>
Song W.
Lu W.
Wang J.
Lu P.
Wang Y.
J. Org. Chem.
2010,
75:
3481
<A NAME="RS03610ST-9B">9b</A>
Yoo EJ.
Park SH.
Lee SH.
Chang S.
Org. Lett.
2009,
11:
1155
<A NAME="RS03610ST-9C">9c</A>
Yoo EJ.
Bae I.
Cho SH.
Han H.
Chang S.
Org.
Lett.
2006,
8:
1347
<A NAME="RS03610ST-10">10</A> For a recent example of α-functionalization
of imidates, see:
Matsubara R.
Berthiol F.
Kobayashi S.
J. Am.
Chem. Soc.
2008,
130:
1804
<A NAME="RS03610ST-11">11</A> For a related 1,3-shift, see:
Bendikov M.
Duong HM.
Bolanos E.
Wudl F.
Org. Lett.
2005,
7:
783
<A NAME="RS03610ST-12A">12a</A> For
leading references, see:
Anderson CE.
Overman LE.
J. Am. Chem. Soc.
2003,
125:
12412
<A NAME="RS03610ST-12B">12b</A> For a review, see:
Overman LE.
Acc. Chem. Res.
1980,
13:
218
Also see:
<A NAME="RS03610ST-12C">12c</A>
Overman LE.
J. Am. Chem. Soc.
1974,
96:
597
<A NAME="RS03610ST-12D">12d</A>
Overman LE.
J. Am. Chem. Soc.
1976,
98:
2901
<A NAME="RS03610ST-13">13</A>
Tomooka K.
Suzuki M.
Uehara K.
Shimada M.
Akiyama T.
Synlett
2008,
2518
<A NAME="RS03610ST-14">14</A>
Selected Experimental
Procedures and Characterizations
Synthesis of Nitrile 8
To a stirring
solution of ynamide 5a (75.0 mg, 0.19 mmol) in
toluene (2 mL) at r.t. was slowly added freshly prepared NaOMe (31.0
mg, 0.58 mmol). After addition, the reaction mixture was sealed
under dry nitrogen and heated to 100 ˚C for 1
h. Over the course of the reaction, TsOMe was observed to precipitate
out of solution and was subsequently removed by filtration of the
crude reaction mixture through a plug of CeliteTM to
afford the pure nitrile 8 (45.6 mg, 0.19 mmol, >95% yield)
as a colorless oil.
R
f
= 0.45
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.00-1.41
(m, 21 H), 2.05 (dd, 1 H, J = 7.5,
4.0 Hz), 2.28-2.34 (m, 1 H), 2.35-2.44 (m, 1 H),
5.14 (d, 1 H, J = 10.5
Hz), 5.17 (d, 1 H, J = 18.0
Hz), 5.88-5.98 (m, 1 H). ¹³C
NMR (125 MHz, CDCl3): δ = 11.3, 14.4,
18.9, 31.8, 117.2, 122.7, 136.2. IR (film): 2946 (m), 2869 (m),
2222 (w), 1595 (m), 1377 (m) cm-¹.
MS (APCI): m/e (%) = 238 (100) [M + H]+.
Synthesis of Alcohol 10
To
a stirring solution of ynamide 9 (315.0
mg, 0.77 mmol) in THF (2 mL) at r.t. was slowly added TBAF (0.85
mL, 1.0 M in THF). After 2 h, the solvent was removed via rotary evaporation,
and the crude oil was purified by flash silica gel column chromatography [isocratic
eluent: hexanes-EtOAc, 1:1] to afford the alcohol 10 (191.0 mg, 0.65 mmol, 85% yield)
as a pale yellow oil.
R
f
= 0.09
(hexanes-EtOAc = 2:1). ¹H
NMR (500 MHz, CDCl3): δ = 1.52 (br
s, 1 H), 1.73 (pent, 2 H, J = 6.5 Hz), 2.38 (t, 2 H, J = 7.0
Hz), 3.71 (d, 2 H, J = 7.0
Hz), 3.91 (d, 2 H, J = 7.0
Hz), 5.19 (d, 1 H, J = 10.5
Hz), 5.24 (d, 1 H, J = 17.5
Hz), 5.72 (ddt, 1 H, J = 17.5,
10.5, 7.0 Hz), 7.34 (d, 2 H, J = 8.0
Hz), 7.78 (d, 2 H, J = 8.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 15.4,
21.9, 31.8, 54.4, 61.9, 69.9, 73.8, 120.0, 128.0, 130.0, 131.4,
135.0, 144.8. IR (film): 3200 (br s), 2981 (m), 2878 (m), 1644 (m)
cm-¹. MS (APCI):
m/e (%) = 294
(100) [M + H]+.
Nitrile
12
R
f
= 0.41
(hexanes-EtOAc, 8:1). ¹H NMR (400 MHz, CDCl3): δ = 0.02
(s, 6 H), 0.86 (s, 9 H), 1.66-1.85 (m, 2 H), 2.05 (dd,
2 H, J = 8.4,
6.8 Hz), 2.48 (s, 3 H), 2.67-2.79 (m, 2 H), 3.59 (t, 2
H, J = 6.0
Hz), 5.24 (d, 1 H, J = 16.8
Hz), 5.26 (d, 1 H, J = 10.0
Hz), 5.82 (ddt, 1 H, J = 17.6,
10.0, 7.2 Hz), 7.40 (d, 2 H, J = 8.0
Hz), 7.88 (d, 2 H, J = 8.4
Hz).
¹³C NMR (100 MHz, CDCl3): δ = 5.2,
18.4, 22.0, 26.1, 28.3, 28.7, 36.8, 62.1, 65.8, 116.9, 121.9, 129.8,
130.2, 131.0, 131.7. IR (film): 2929 (m), 2857 (m), 2238 (w), 1596
(m), 1331 (s), 1150 (s) cm-¹. MS (APCI): m/e (%) = 408
(100)
[M + H]+,
ESI-HRMS: m/e calcd for C21H33NO3SSiNa: 430.1843;
found: 430.1860.
Synthesis of Compound
13
To a solution of
ynamide 10 (75.0 mg, 0.26 mmol) in THF (5
mL) at 0 ˚C was added NaH (19.0 mg, 0.46 mmol,
60% wt/wt in mineral oil). The reaction mixture
was warmed to r.t. and stirred for 20 min to allow for complete
deproto-nation and then sealed under dry nitrogen and heated to 85 ˚C
for 3 h. The reaction mixture was quenched with H2O, and
the organic phase was extracted with EtOAc and then dried over Na2SO4.
Removal of the solvent by rotary evaporation and purification by
flash silica gel column chromatography (hexanes-EtOAc,
4:1) afforded 13 (50.0 mg, 0.17 mmol, 65% yield)
as a colorless oil.
Compound 13
R
f
= 0.35
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.90
(pent, 2 H, J = 9.5
Hz), 2.40 (s, 3 H), 2.49 (td, 2 H, J = 9.5,
2.0 Hz), 3.96 (t, 2 H, J = 8.0
Hz), 3.97 (d, 2 H, J = 8.5
Hz), 4.86 (s, 1 H), 5.06 (dd, 1 H, J = 13.0,
2.0 Hz), 5.14 (dd, 1 H, J = 20.0,
2.0 Hz), 5.76 (ddt, 1 H, J = 20.0, 13.0,
8.5 Hz), 7.26 (d, 2 H, J = 9.5
Hz), 7.70 (d, 2 H, J = 9.5 Hz). ¹³C
NMR (125 MHz, CDCl3): δ = 21.8, 24.6,
28.4, 52.3, 72.0, 94.9, 117.6, 127.7, 129.4, 134.1, 136.9, 143.1,
157.4. IR (film): 3055 (m), 2980 (m), 1597 (s), 1337 (s) cm-¹.
MS
(APCI): m/e (%) = 294
(100) [M + H]+. ESI-HRMS:
m/e calcd for C15H19NO3SNa:
316.0978; found: 316.0986.
Compound
14
R
f
= 0.38
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.99
(pent, 2 H, J = 7.0
Hz), 2.43 (s, 3 H), 2.80 (td, 2 H, J = 8.0,
2.0 Hz), 3.66 (d, 2 H, J = 6.5
Hz), 4.16 (t, 2 H, J = 6.5
Hz), 4.76 (t, 1 H, J = 2.0
Hz), 5.08-5.13 (m, 2 H), 5.70 (ddt, 1 H, J = 17.0,
10.0, 6.5 Hz), 7.30 (d, 2 H, J = 8.0 Hz),
7.67 (d, 2 H, J = 8.5
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 21.8,
24.4, 28.1, 54.8, 72.1, 97.8, 119.1, 127.9, 129.8, 133.1, 135.0,
143.5, 166.8. MS (APCI): m/e (%) = 294
(20) [M + H]+.
General Procedure for the Synthesis of Imidates
4a-l
To a
flame-dried vial containing 4 Å MS was added the appropriate
ynamide and anhydrous alcohol solvent (0.04 M in ynamide). The reaction
mixture was sealed under dry nitrogen and heated to 75-95 ˚C
for 2-5 d. Upon cooling to r.t., the mixture was filtered
through a plug of CeliteTM. Removal of the alcohol solvent
in vacuo followed by flash
silica gel column
chromatography afforded the respective imidate.
Imidate 4a
R
f
= 0.45
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.15
(d, 9 H, J = 7.5
Hz), 1.20 (d, 9 H, J = 7.5 Hz),
1.35 (sept, 3 H, J = 7.5
Hz), 2.46 (s, 3 H), 2.50 (m, 1 H), 2.62 (ddd, 1 H, J = 20.5,
12.5, 8.5 Hz), 3.71 (dd, 1 H, J = 3.0, 12.0
Hz), 3.73 (s, 3 H), 4.92 (dd, 1 H, J = 10.0,
1.0 Hz), 5.00 (ddt, 1 H, J = 17.0,
3.0, 1.5 Hz), 5.73 (dddd, 1 H, J = 22.5, 14.0,
8.5, 5.5 Hz), 7.31 (d, 2 H, J = 8.0
Hz), 7.86 (d, 2 H, J = 8.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8,
19.1, 19.1, 21.8, 32.6, 34.2, 54.0, 115.8, 126.9, 129.4, 137.5, 140.2,
143.0, 178.4. IR (film): 2948 (m), 2868 (m), 1582 (s), 1288 (s)
cm-¹. MS (APCI): m/e (%) = 424
(100) [M + H]+. ESI-HRMS: m/e calcd for C22H37NO3SSiNa:
446.2156; found: 446.2161.
Imidate
4b
R
f
= 0.38
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.11
(d, 9 H, J = 7.5
Hz), 1.16 (d, 9 H, J = 7.5 Hz),
1.24 (t, 3 H, J = 7.0
Hz), 1.31 (sept, 3 H, J = 7.5
Hz), 2.41 (s, 3 H), 2.59 (dt, 1 H, J = 13.5,
9.0 Hz), 3.64 (dd, 1 H, J = 12.5,
3.0 Hz), 4.04-4.17 (m, 2 H), 4.87 (d, 1 H, J = 10.0 Hz),
4.95 (d, 1 H, J = 16.5
Hz), 5.63-5.73 (m, 1 H), 7.26 (d, 2 H, J = 7.5
Hz), 7.80 (d, 2 H, J = 8.5
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.7,
13.9, 19.1, 19.1, 21.7, 32.4, 34.2, 64.2, 115.7, 126.8, 129.3, 137.5,
140.2, 142.8, 177.8. IR (film): 2948 (m), 2871 (m), 1965 (w), 1575
(s), 1289 (s), 1155 (s) cm-¹. MS (APCI): m/e (%) = 438
(100) [M + H]+. ESI-HRMS: m/e calcd for C23H39NO3SSiNa:
460.2313; found: 460.2295.
Imidate
4c
R
f
= 0.19
(hexanes-EtOAc, 15:1). ¹H NMR (500
MHz, CDCl3): δ = 1.13 (d, 9 H, J = 7.5 Hz),
1.14 (d, 3 H, J = 6.0 Hz),
1.15 (d, 9 H, J = 7.5
Hz), 1.25 (d, 3 H, J = 6.0
Hz), 1.31 (sept, 3 H, J = 7.5
Hz), 2.41 (s, 3 H), 2.40-2.48 (m, 1 H), 2.57 (dt, 1 H, J = 14.0,
8.5 Hz), 2.84 (dd, 1 H, J = 12.0,
3.0 Hz), 4.86 (d, 1 H, J = 10.0
Hz), 4.96 (dd, 1 H, J = 17.0,
1.0 Hz), 5.03 (sept, 1 H, J = 6.0
Hz), 5.68 (dddd, 1 H, J = 17.0, 10.0,
8.5, 5.5 Hz), 7.26 (d, 2 H, J = 8.0
Hz), 7.80 (d, 2 H, J = 8.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8,
19.2, 21.6, 21.7, 21.8, 32.4, 34.4, 71.9, 115.8, 126.8, 129.3, 137.4, 140.4,
142.7, 177.2. IR (film): 2946 (m), 2868 (m), 1570 (s), 1464 (m),
1287 (m), 1153 (s) cm-¹. MS (APCI): m/e (%) = 410
(100) [M - propene + H]+.
ESI-HRMS: m/e calcd for C24H41NO3SSiNa:
474.2469; found: 474.2446.
Imidate
4d
R
f
= 0.41
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.12
(d, 9 H, J = 9.5
Hz), 1.15 (d, 9 H, J = 9.5 Hz),
1.31 (sept, 3 H, J = 9.5
Hz), 1.50-1.82 (m, 8 H), 2.41 (s, 3 H), 2.40-2.47
(m, 1 H), 2.55 (dt, 1 H, J = 18.0,
10.5 Hz), 3.64 (dd, 1 H, J = 15.5,
4.0 Hz), 4.86 (d, 1 H, J = 12.5
Hz), 4.94 (d, 1 H, J = 21.0
Hz), 5.12-5.16 (m, 1 H), 5.62-5.74 (m, 1 H), 7.25
(d, 2 H, J = 10.0
Hz), 7.80 (d, 2 H, J = 10.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8,
19.2, 21.7, 23.8, 24.2, 32.2, 32.9, 34.4, 81.4, 115.6, 126.8, 129.3,
137.6, 140.5, 142.7, 117.5. IR (film): 2946 (m), 2869 (m), 1571
(s), 1463 (w), 1287 (m), 1153 (s) cm-¹.
MS (APCI): m/e (%) = 410
(100) [M - cyclopentene + H]+.
ESI-HRMS: m/e calcd for C26H43NO3SSiNa:
500.2626; found: 500.2618.
Imidate
4e
R
f
= 0.42
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.12
(d, 9 H, J = 9.0
Hz), 1.16 (d, 9 H, J = 9.5 Hz),
1.26 (t, 3 H, J = 9.0
Hz), 1.32 (sept, 3 H, J = 9.5
Hz), 2.44-2.52 (m, 1 H), 2.61 (dt, 1 H, J = 17.5,
11.0 Hz), 3.59 (dd, 1 H, J = 15.5,
4.0 Hz), 4.05-4.15 (m, 2 H), 4.93 (d, 1 H, J = 12.5 Hz),
4.99 (d, 1 H, J = 21.0
Hz), 5.71-5.82 (m, 1 H), 8.09 (d, 2 H, J = 11.5
Hz), 8.32 (d, 2 H, J = 11.5
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8,
13.9, 19.0, 19.1, 33.5, 34.3, 64.8, 116.1, 124.2, 128.0, 137.3,
148.6, 179.5. IR (film): 2943 (w), 2868 (w), 1566 (s), 1531 (s),
1295 (s), 1159 (s) cm-¹. MS (APCI): m/e (%) = 469
(100) [M + H]+. ESI-HRMS: m/e calcd for C22H36N2O5SSiNa:
491.2007; found: 491.2007.
Imidate
4f
R
f
= 0.27
(hexanes-EtOAc, 15:1). ¹H NMR (400
MHz, CDCl3): δ = 1.14 (d, 9 H, J = 7.2 Hz),
1.15 (d, 3 H, J = 6.4 Hz),
1.17 (d, 9 H, J = 7.6
Hz), 1.28 (d, 3 H, J = 6.4
Hz), 1.32 (sept, 3 H, J = 7.6
Hz), 2.46-2.52 (m, 1 H), 2.60 (dt, 1 H, J = 14.4,
8.8 Hz), 3.61 (dd, 1 H, J = 12.0,
3.6 Hz), 4.93 (d, 1 H, J = 10.0
Hz), 4.96-5.04 (m, 2 H), 5.76 (dddd, 1 H, J = 17.0,
10.0, 8.8, 5.2 Hz), 8.10 (d, 2 H, J = 9.2
Hz), 8.33 (d, 2 H, J = 8.8
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8, 19.1,
19.1, 21.5, 21.8, 33.4, 34.4, 72.9, 116.1, 124.2, 128.0, 137.3,
148.7, 149.9, 178.9. IR (film): 2946 (m), 2869 (m), 1562 (s), 1531
(s), 1349 (s), 1296 (s), 1156 (s) cm-¹.
MS (APCI): m/e (%) = 441
(30) [M - propene + H]+.
ESI-HRMS: m/e calcd for C23H38N2O5SSiNa:
505.2163; found: 505.2164.
Imidate
4g
R
f
= 0.36
(hexanes-EtOAc, 10:1). ¹H NMR (400
MHz, CDCl3): δ = 1.13 (d, 9 H, J = 7.2 Hz),
1.16 (d, 9 H, J = 7.6 Hz),
1.33 (sept, 3 H, J = 7.6
Hz), 1.50-1.88 (m, 8 H), 2.46-2.51 (m, 1 H), 2.58
(dt, 1 H, J = 14.0,
8.4 Hz), 3.60 (dd, 1 H, J = 12.0,
3.2 Hz), 4.92 (d, 1 H, J = 10.0
Hz), 5.00 (d, 1 H, J = 16.8
Hz), 5.09-5.14 (m, 1 H), 5.70-5.82 (m, 1 H), 8.11 (d,
2 H, J = 8.4
Hz), 8.33 (d, 2 H, J = 8.8
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 11.8,
19.1, 23.8, 24.1, 32.2, 32.9, 33.2, 34.4, 82.2, 116.0, 124.1, 128.0,
137.4, 148.7, 149.9, 179.1. IR (film): 2947 (m), 2871 (m), 1565
(s), 1531 (s), 1349 (s), 1303 (m), 1157 (s) cm-¹.
MS (APCI): m/e (%) =
441 (30)
[M - cyclopentene + H]+.
ESI-HRMS: m/e calcd for C25H40N2O5SSiNa:
531.2320; found: 530.2333.
Imidate 4h
R
f
= 0.30
(hexanes-EtOAc, 4:1). ¹H NMR (400 MHz, CDCl3): δ = 2.43
(s, 3 H), 3.59 (tt, 2 H, J = 6.0,
1.2 Hz), 3.69 (s, 3 H), 4.49 (t, 1 H, 6.0 Hz), 5.10 (ddt, 1 H, J = 10.4,
2.8, 1.6 Hz), 5.16 (ddt, 1 H, J = 17.2,
2.8, 1.6 Hz), 5.72 (ddt, 1 H, J = 17.2,
10.4, 6.0), 7.24-7.34 (m, 7 H), 7.76 (d, 2 H, J = 8.4 Hz). ¹³C
NMR (100 MHz, CDCl3): δ = 21.6, 41.3,
45.8, 52.2, 117.7, 127.2, 127.3, 128.7, 129.4, 129.8, 133.2, 134.1, 137.1,
143.6, 172.2. IR (film): 3034 (m), 2951 (m), 1735 (s), 1597 (m),
1325 (s) cm-¹. MS (APCI): m/e (%) = 344
(100) [M + H]+. ESI-HRMS: m/e calcd for C19H21NO3SNa: 366.1135;
found: 366.1150.
Imidate 4i
R
f
= 0.48
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.26
(t, 3 H, J = 7.0
Hz), 2.41 (s, 3 H), 2.63 (dt, 1 H, J = 13.5,
6.5 Hz) 2.83 (dt, 1 H, J = 16.5,
8.0 Hz), 4.09 (dq, 1 H, J = 11.0,
7.0 Hz), 4.19 (dq, 1 H, J = 11.0,
7.0 Hz), 4.98-5.04 (m, 2 H), 5.10 (dd, 1 H, J = 17.0,
1.5 Hz), 5.70-5.80 (m, 1 H), 7.23-7.28 (m, 3 H),
7.32 (t, 2 H, J = 8.0
Hz), 7.46 (d, 2 H, J = 7.5
Hz), 7.77 (d, 2 H, J = 8.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 13.7,
21.7, 36.0, 37.9, 48.9, 64.6, 117.7, 126.9, 127.8, 128.8, 129.0,
129.5, 134.9, 137.8, 143.3, 174.6. IR (film): 2985 (w), 1592 (s),
1301 (s), 1152 (s) cm-¹. MS (APCI): m/e (%) = 358
(100) [M + H]+. ESI-HRMS: m/e calcd for C20H23NO3SNa:
380.1291; found: 380.1287.
Imidate 4j
R
f
= 0.32
(hexanes-EtOAc, 6:1). ¹H NMR (500 MHz, CDCl3): δ = 1.14
(d, 3 H, J = 6.0
Hz), 1.25 (d, 3 H, J = 6.5 Hz),
2.40 (s, 3 H), 2.59 (dt, 1 H, J = 12.5,
5.5 Hz), 2.80 (dt, 1 H, J = 14.5,
8.5 Hz), 4.97 (m, 3 H), 5.10 (d, 1 H, J = 17.5 Hz),
5.70-5.79 (m, 1 H), 7.22-7.27 (m, 3 H), 7.31 (t,
2 H, J = 7.5
Hz), 7.44 (d, 2 H, J = 8.0
Hz), 7.75 (d, 2 H, J = 8.5 Hz). ¹³C
NMR (125 MHz, CDCl3): δ = 21.3, 21.4,
21.7, 38.1, 48.9, 72.5, 117.7, 126.8, 127.7, 128.7, 128.8, 129.5,
134.8, 137.9, 139.7, 143.1, 174.0. IR (film): 2984 (w), 1592 (s), 1302
(s), 1156 (s) cm-¹. MS (APCI): m/e (%) = 330
(100)
[M - propene + H]+.
ESI-HRMS: m/e calcd for C21H25NO3SNa:
394.1448; found: 394.1440.
Imidate 4k
R
f
= 0.33
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.25
(t, 3 H, J = 7.0
Hz), 2.62 (dt, 1 H, J = 13.5, 7.0
Hz), 2.83 (dt, 1 H, J = 15.5,
8.5 Hz), 3.84 (s, 3 H), 4.09 (dq, 1 H, J = 11.0,
7.0 Hz), 4.18 (dq, 1 H, J = 11.0,
7.0 Hz), 4.99-5.04 (m, 2 H), 5.09 (d, 1 H, J = 17.0 Hz),
5.70-5.59 (m, 1 H), 6.91 (d, 2 H, J = 9.0
Hz), 7.26 (t, 1 H, J = 7.5
Hz), 7.32 (d, 2 H, J = 7.5
Hz), 7.45 (d, 2 H, J = 7.5
Hz), 7.81 (d, 2 H, J = 9.0
Hz). ¹³C NMR (100 MHz, CDCl3): δ = 13.7,
37.9, 48.8, 55.7, 64.8, 114.0, 117.7, 127.7, 128.8, 128.9, 128.9, 133.1,
134.9, 137.8, 162.9, 174.4. IR (film): 2986 (w), 1593 (s), 1499
(m), 1298 (s), 1150 (s) cm-¹. MS (APCI):
m/e (%) = 374
(100) [M + H]+. ESI-HRMS: m/e calcd for C20H23NO4SNa:
396.1231; found: 396.1240.
Imidate
4l
R
f
= 0.20
(hexanes-EtOAc, 4:1). ¹H NMR (500 MHz, CDCl3): δ = 1.55-1.83
(m, 8 H), 2.59 (dt, 1 H, J = 12.5,
6.5 Hz), 2.79 (dt, 1 H, J = 17.0,
8.0 Hz), 3.85 (s, 3 H), 4.99 (dd, 1 H, J = 9.0,
7.0 Hz), 5.02 (d, 1 H, J = 11.0
Hz), 5.09 (dd, 1 H, J = 17.0,
1.5 Hz), 5.12-5.17 (m, 1 H), 5.74 (dddd, 1 H, J = 17.0,
10.0, 7.5, 5.5 Hz), 6.92 (d, 2 H, J = 9.0
Hz), 7.24-7.28 (m, 1 H), 7.31 (t, 2 H, J = 7.0
Hz), 7.43 (d, 2 H, J = 7.5 Hz),
7.81 (d, 2 H, J = 9.0
Hz). ¹³C NMR (125 MHz, CDCl3): δ = 24.0,
32.4, 32.6, 38.0, 48.8, 55.8, 81.8, 114.0, 117.6, 127.7, 128.7,
128.8 128.8, 134.6, 134.9, 137.9, 162.7, 173.9. IR (film): 2968
(w), 2850 (w), 1579 (s), 1294 (s), 1257 (s), 1150 (s) cm-¹.
MS (APCI): m/e (%) = 346
(100) [M - cyclopentene + H]+.
ESI-HRMS: m/e calcd for C23H27NO4SNa:
436.1553; found: 436.1552.
Imidate
15
R
f
= 0.50
(hexanes-EtOAc, 4:1). ¹H NMR (400 MHz, CDCl3): δ = 1.11
(d, 9 H, J = 7.6
Hz), 1.17 (d, 9 H, J = 7.6 Hz),
1.31 (sept, 3 H, J = 7.6
Hz), 2.41 (s, 3 H), 2.43-2.48 (m, 1 H), 2.61 (td, 1 H, J = 13.6,
8.8 Hz), 3.67 (dd, 1 H, J = 12.0, 3.2
Hz), 4.47 (dd, 1 H, J = 12.8,
6.0 Hz), 4.59 (dd, J = 12.8, 6.0
Hz), 4.87 (d, 1 H, J = 10.0
Hz), 4.95 (d, 1 H, J = 17.2 Hz),
5.22 (d, 1 H, J = 10.4
Hz), 5.28 (dd, 1 H, J = 16.0,
1.2 Hz), 5.63-5.74 (m, 1 H), 5.87 (ddt, 1 H, J = 16.8,
10.0, 6.0 Hz), 7.26 (d, 2 H, J = 8.0
Hz), 7.80 (d, 2 H, J = 8.4
Hz).
¹³C NMR (100 MHz, CDCl3): δ = 11.8,
19.1, 21.7, 32.5, 34.2, 69.1, 115.9, 119.8, 126.8, 126.9, 129.4,
131.6, 137.4, 140.1, 142.9, 177.4 cm-¹.
IR (film): 2943 (m), 2869 (m), 1584 (s), 1302 (m), 1155 (s) cm-¹.
MS (APCI): m/e (%) = 450
(100) [M + H]+. ESI-HRMS: m/e calcd for C24H39NO3SSiNa:
472.2313; found: 472.2305.
Synthesis
of Amide 16
To a stirring
solution of imidate 15 (35.0 mg, 0.078
mmol) in DCE (0.4 mL) was added PdCl2(PhCN)2 (1.5
mg, 0.004 mol). The reaction was stirred under a nitrogen atmosphere for
3 h at r.t., and then the solvent was removed by rotary evaporation.
The crude residue was purified by flash silica gel column chromatography [isocratic
eluent: hexanes-EtOAc, 20:1] to afford the amide 16 (35.0 mg, 0.078 mmol, >95% yield)
as a colorless oil.
R
f
= 0.50
(hexanes-EtOAc, 4:1). ¹H NMR (400 MHz, CDCl3): δ = 1.05
(d, 9 H, J = 6.8
Hz), 1.11 (d, 9 H, J = 6.8 Hz),
1.13-1.25 (m, 3 H), 2.26 (dd, 1 H, J = 11.6,
6.4 Hz), 2.43 (s, 3 H), 2.66 (td, 1 H, J = 13.2,
7.2 Hz), 3.00 (br s, 1 H), 4.34 (dd, 1 H, J = 16.4,
6.8 Hz), 4.47-4.54 (m, 1 H), 4.69 (d, 1 H, J = 10.0 Hz),
4.82 (d, 1 H, J = 16.8
Hz), 5.21 (d, 1 H, J = 10.0
Hz), 5.27 (d, 1 H, J = 17.2
Hz), 5.21-5.37 (m, 1 H), 7.29 (d, 2 H, J = 8.8
Hz), 7.83 (d, 2 H, J = 8.4
Hz). ¹³C NMR (100 MHz, CDCl3): δ = 11.8,
18.8, 19.2, 21.8, 34.8, 49.5, 116.0, 119.0, 128.0, 128.8, 129.5,
133.6, 137.4, 144.6, 176.0. IR (film): 2950 (m), 2870 (m), 1678
(s), 1352 (s)
cm-¹. MS (APCI): m/e (%) = 450
(100) [M + H]+. ESI-HRMS: m/e calcd for C24H39NO3SSiNa:
472.2313; found: 472.2317.
Synthesis of Azapin-2-one 17
To
a solution of amide 16 (35.0 mg, 0.078
mmol) in DCE was added Grubbs I catalyst (3.2 mg, 0.004 mmol). The reaction
vial was flushed with dry nitrogen, sealed, and heated to 70 ˚C
for 16 h. The solvent was removed by rotary evaporation, and the
crude residue was purified by flash silica gel column chromatography [isocratic
eluent: hexanes-EtOAc, 10:1] to afford azapin-2-one 17 (29.5 mg, 0.070 mmol, 90% yield)
as a white solid.
R
f
= 0.30
(hexanes-EtOAc, 8:1). Mp 129-130 ˚C.
¹H
NMR (500 MHz, CDCl3): δ = 0.95 (d,
9 H, J = 7.5
Hz), 0.99 (d, 9 H, J = 7.5
Hz), 1.18 (sept, 3 H, J = 7.5
Hz), 2.28-2.40 (m, 1 H), 2.41 (s, 3 H), 2.41-2.48
(m, 1 H), 2.90 (dd, 1 H, J = 13.0,
2.5 Hz), 4.49 (dt, 1 H, J = 18.0,
3.0 Hz), 4.81 (dd, 1 H, J = 18.0,
8.0 Hz), 5.75-5.79 (m, 1 H), 5.83-5.88 (m, 1 H),
7.26 (d, 2 H, J = 8.0
Hz), 7.83 (d, 2 H, J = 8.0
Hz). ¹³C NMR (120 MHz, CDCl3): δ = 11.2,
19.3, 21.8, 28.1, 31.0, 43.1, 123.9, 128.5, 129.3, 133.6, 136.8,
144.3, 175.4. IR (film): 2943 (m), 2866 (m), 1963 (s), 1597 (w),
1350 (s) cm-¹. MS (APCI): m/e (%) = 422
(100) [M + H]+. ESI-HRMS: m/e calcd for C22H35NO3SSiNa:
444.2000; found: 444.2000.